Trial Outcomes & Findings for Survey on Anemia Therapy in Participants With Chronic Kidney Disease (CKD) Not on Dialysis (NCT NCT02238067)
NCT ID: NCT02238067
Last Updated: 2017-03-24
Results Overview
Assessment was performed by physician via a satisfaction survey on anemia treatment. ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type was reported.
Recruitment status
COMPLETED
Target enrollment
196 participants
Primary outcome timeframe
Baseline
Results posted on
2017-03-24
Participant Flow
Participant milestones
| Measure |
Chronic Renal Anemia Participants
Participants with Chronic Kidney Disease (CKD) who were not on dialysis and treated with Erythropoiesis-Stimulating Agents (ESA) according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Overall Study
STARTED
|
196
|
|
Overall Study
COMPLETED
|
151
|
|
Overall Study
NOT COMPLETED
|
45
|
Reasons for withdrawal
| Measure |
Chronic Renal Anemia Participants
Participants with Chronic Kidney Disease (CKD) who were not on dialysis and treated with Erythropoiesis-Stimulating Agents (ESA) according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Overall Study
Not completed survey at Month 6
|
45
|
Baseline Characteristics
Survey on Anemia Therapy in Participants With Chronic Kidney Disease (CKD) Not on Dialysis
Baseline characteristics by cohort
| Measure |
Chronic Renal Anemia Participants
n=196 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Age, Continuous
|
74.6 years
STANDARD_DEVIATION 10.6 • n=5 Participants
|
|
Sex: Female, Male
Female
|
85 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
111 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: BaselinePopulation: All enrolled participants
Assessment was performed by physician via a satisfaction survey on anemia treatment. ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=196 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by ESA Types at Baseline
Mircera
|
51.5 percentage of participants
Interval 44.3 to 58.7
|
|
Percentage of Participants by ESA Types at Baseline
Recormon
|
17.3 percentage of participants
Interval 12.3 to 23.4
|
|
Percentage of Participants by ESA Types at Baseline
Eprex
|
10.7 percentage of participants
Interval 6.8 to 15.9
|
|
Percentage of Participants by ESA Types at Baseline
Aranesp
|
20.4 percentage of participants
Interval 15.0 to 26.7
|
PRIMARY outcome
Timeframe: Month 6Population: All enrolled participants who completed the questionnaire at Month 6
Assessment was performed by physician via a satisfaction survey on anemia treatment. ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=151 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by ESA Types at Month 6
Mircera
|
43.7 percentage of participants
Interval 35.7 to 52.0
|
|
Percentage of Participants by ESA Types at Month 6
Recormon
|
19.2 percentage of participants
Interval 13.3 to 26.4
|
|
Percentage of Participants by ESA Types at Month 6
Eprex
|
12.6 percentage of participants
Interval 7.7 to 19.0
|
|
Percentage of Participants by ESA Types at Month 6
Aranesp
|
24.5 percentage of participants
Interval 17.9 to 32.2
|
PRIMARY outcome
Timeframe: BaselinePopulation: All enrolled participants. Number of participants analyzed = participants evaluable for this outcome measure.
Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). Percentage of participants by each frequency of ESA use was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=195 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by Frequency of ESA Use at Baseline
Three times a week
|
2.6 percentage of participants
Interval 0.8 to 5.9
|
|
Percentage of Participants by Frequency of ESA Use at Baseline
Twice a week
|
7.2 percentage of participants
Interval 4.0 to 11.8
|
|
Percentage of Participants by Frequency of ESA Use at Baseline
Once a week
|
14.9 percentage of participants
Interval 10.2 to 20.7
|
|
Percentage of Participants by Frequency of ESA Use at Baseline
Every 2 weeks
|
26.2 percentage of participants
Interval 20.1 to 32.9
|
|
Percentage of Participants by Frequency of ESA Use at Baseline
Every 4 weeks
|
38.5 percentage of participants
Interval 31.6 to 45.7
|
|
Percentage of Participants by Frequency of ESA Use at Baseline
Other
|
10.8 percentage of participants
Interval 6.8 to 16.0
|
PRIMARY outcome
Timeframe: Month 6Population: All enrolled participants who completed the questionnaire at Month 6
Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). Percentage of participants by each frequency of ESA use was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=151 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by Frequency of ESA Use at Month 6
Three times a week
|
1.3 percentage of participants
Interval 0.2 to 4.7
|
|
Percentage of Participants by Frequency of ESA Use at Month 6
Twice a week
|
4.0 percentage of participants
Interval 1.5 to 8.4
|
|
Percentage of Participants by Frequency of ESA Use at Month 6
Once a week
|
15.9 percentage of participants
Interval 10.5 to 22.7
|
|
Percentage of Participants by Frequency of ESA Use at Month 6
Every 2 weeks
|
25.2 percentage of participants
Interval 18.5 to 32.9
|
|
Percentage of Participants by Frequency of ESA Use at Month 6
Every 4 weeks
|
39.1 percentage of participants
Interval 31.2 to 47.3
|
|
Percentage of Participants by Frequency of ESA Use at Month 6
Other
|
14.6 percentage of participants
Interval 9.4 to 21.2
|
PRIMARY outcome
Timeframe: BaselinePopulation: All enrolled participants. Number of participants analyzed = participants evaluable for this outcome measure. Here 'n' signifies number of participants evaluable for specified categories.
Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type and each frequency of ESA use was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=195 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Recormon : Three times a week (n=34)
|
0 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Recormon : Twice a week (n=34)
|
17.6 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Eprex : Every 4 weeks (n=21)
|
4.8 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Mircera : Three times a week (n=100)
|
2.0 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Mircera : Twice a week (n=100)
|
4.0 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Eprex : Every 2 weeks (n=21)
|
9.5 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Mircera : Once a week (n=100)
|
1.0 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Mircera : Every 2 weeks (n=100)
|
26.0 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Mircera : Every 4 weeks (n=100)
|
67.0 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Mircera : Other (n=100)
|
0 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Eprex : Other (n=21)
|
23.8 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Aranesp : Three times a week (n=40)
|
2.5 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Recormon : Once a week (n=34)
|
38.2 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Aranesp : Twice a week (n=40)
|
5.0 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Aranesp : Once a week (n=40)
|
15.0 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Aranesp : Every 2 weeks (n=40)
|
42.5 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Recormon : Every 2 weeks (n=34)
|
17.6 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Aranesp : Every 4 weeks (n=40)
|
12.5 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Aranesp : Other (n=40)
|
22.5 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Recormon : Every 4 weeks (n=34)
|
5.9 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Recormon : Other (n=34)
|
20.6 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Eprex : Three times a week (n=21)
|
9.5 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Eprex : Twice a week (n=21)
|
9.5 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Baseline
Eprex : Once a week (n=21)
|
42.9 percentage of participants
|
PRIMARY outcome
Timeframe: Month 6Population: All enrolled participants who completed the questionnaire at Month 6. Here 'n' signifies number of participants evaluable for specified categories.
Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type and each frequency of ESA use was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=151 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Mircera : Three times a week (n=66)
|
1.5 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Mircera : Twice a week (n=66)
|
1.5 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Mircera : Once a week (n=66)
|
0 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Mircera : Every 2 weeks (n=66)
|
18.2 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Mircera : Every 4 weeks (n=66)
|
71.2 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Mircera : Other (n=66)
|
7.6 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Aranesp : Every 4 weeks (n=37)
|
24.3 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Recormon : Three times a week (n=29)
|
0 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Recormon : Twice a week (n=29)
|
10.3 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Recormon : Once a week (n=29)
|
27.6 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Recormon : Every 2 weeks (n=29)
|
37.9 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Recormon : Every 4 weeks (n=29)
|
6.9 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Aranesp : Other (n=37)
|
21.6 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Recormon : Other (n=29)
|
17.2 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Eprex : Three times a week (n=19)
|
5.3 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Eprex : Twice a week (n=19)
|
5.3 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Eprex : Once a week (n=19)
|
47.4 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Eprex : Every 2 weeks (n=19)
|
15.8 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Eprex : Every 4 weeks (n=19)
|
5.3 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Eprex : Other (n=19)
|
21.1 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Aranesp : Three times a week (n=37)
|
0 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Aranesp : Twice a week (n=37)
|
2.7 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Aranesp : Once a week (n=37)
|
18.9 percentage of participants
|
|
Percentage of Participants by Frequency and Types of ESA Used at Month 6
Aranesp : Every 2 weeks (n=37)
|
32.4 percentage of participants
|
SECONDARY outcome
Timeframe: Baseline, Month 6Population: All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points.
Assessment was performed by physician via a satisfaction survey on anemia treatment. CKD stages were based on participant's answer to the survey question. No specific method of assessment for CKD stage was specified. Percentage of participants with each CKD stage was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=196 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by Different CKD Stages
Stage 1 : Baseline (n=196)
|
2.0 percentage of participants
|
|
Percentage of Participants by Different CKD Stages
Stage 1 : Month 6 (n=151)
|
1.3 percentage of participants
|
|
Percentage of Participants by Different CKD Stages
Stage 2 : Baseline (n=196)
|
10.2 percentage of participants
|
|
Percentage of Participants by Different CKD Stages
Stage 2 : Month 6 (n=151)
|
13.9 percentage of participants
|
|
Percentage of Participants by Different CKD Stages
Stage 3 : Baseline (n=196)
|
37.8 percentage of participants
|
|
Percentage of Participants by Different CKD Stages
Stage 3 : Month 6 (n=151)
|
41.7 percentage of participants
|
|
Percentage of Participants by Different CKD Stages
Stage 4 : Baseline (n=196)
|
37.8 percentage of participants
|
|
Percentage of Participants by Different CKD Stages
Stage 4 : Month 6 (n=151)
|
30.5 percentage of participants
|
|
Percentage of Participants by Different CKD Stages
Stage 5 : Baseline (n=196)
|
12.2 percentage of participants
|
|
Percentage of Participants by Different CKD Stages
Stage 5 : Month 6 (n=151)
|
12.6 percentage of participants
|
SECONDARY outcome
Timeframe: Baseline, Month 6Population: All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points.
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked: 'How do you currently inject the anemia treatment?' and reported any of the 5 possible answers: Independently, by a family member, nurse at home, nurse at the clinic or other. Percentage of participants with each injection administration modes was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=196 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by Different Injection Administration Modes
Independently : Baseline (n=196)
|
18.4 percentage of participants
|
|
Percentage of Participants by Different Injection Administration Modes
Nurse at home : Month 6 (n=151)
|
3.3 percentage of participants
|
|
Percentage of Participants by Different Injection Administration Modes
Nurse at the clinic : Baseline (n=196)
|
58.2 percentage of participants
|
|
Percentage of Participants by Different Injection Administration Modes
Nurse at the clinic : Month 6 (n=151)
|
52.3 percentage of participants
|
|
Percentage of Participants by Different Injection Administration Modes
Other: Baseline (n=196)
|
3.1 percentage of participants
|
|
Percentage of Participants by Different Injection Administration Modes
Other : Month 6 (n=151)
|
3.3 percentage of participants
|
|
Percentage of Participants by Different Injection Administration Modes
Independently : Month 6 (n=151)
|
23.2 percentage of participants
|
|
Percentage of Participants by Different Injection Administration Modes
By a family member : Baseline (n=196)
|
16.8 percentage of participants
|
|
Percentage of Participants by Different Injection Administration Modes
By a family member : Month 6 (n=151)
|
17.9 percentage of participants
|
|
Percentage of Participants by Different Injection Administration Modes
Nurse at home : Baseline (n=196)
|
3.6 percentage of participants
|
SECONDARY outcome
Timeframe: Baseline, Month 6Population: All enrolled participants who did not inject independently. Here 'n' signifies number of participants evaluable at specified time-points.
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants responded 'yes' or 'no' to the question: 'Would you be interested in learning to inject independently?' ' Percentage of participants who responded 'yes', was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=160 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants With Interest in Learning to Inject Independently
Baseline (n=160)
|
6.3 percentage of participants
Interval 3.0 to 11.2
|
|
Percentage of Participants With Interest in Learning to Inject Independently
Month 6 (n=116)
|
4.3 percentage of participants
Interval 1.4 to 9.8
|
SECONDARY outcome
Timeframe: Baseline, Month 6Population: All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points.
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their need for improvement in the frequency of treatment received currently on a 1-5 scale, where 1 represents 'Convenient, there is no need for improvement' and 5 represents 'Improvement is very necessary'. Percentage of participants with each score was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=196 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by Need for Improvement in Treatment Frequency
Score 1 : Baseline (n=196)
|
94.9 percentage of participants
Interval 90.8 to 97.5
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency
Score 1 : Month 6 (n=151)
|
96.0 percentage of participants
Interval 91.6 to 98.5
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency
Score 2 : Baseline (n=196)
|
1.5 percentage of participants
Interval 0.3 to 4.4
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency
Score 2 : Month 6 (n=151)
|
1.3 percentage of participants
Interval 0.2 to 4.7
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency
Score 3 : Baseline (n=196)
|
1.5 percentage of participants
Interval 0.3 to 4.4
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency
Score 3 : Month 6 (n=151)
|
1.3 percentage of participants
Interval 0.2 to 4.7
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency
Score 4 : Baseline (n=196)
|
1.5 percentage of participants
Interval 0.3 to 4.4
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency
Score 4 : Month 6 (n=151)
|
0.7 percentage of participants
Interval 0.0 to 3.6
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency
Score 5 : Baseline (n=196)
|
0.5 percentage of participants
Interval 0.0 to 2.8
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency
Score 5 : Month 6 (n=151)
|
0.7 percentage of participants
Interval 0.0 to 3.6
|
SECONDARY outcome
Timeframe: Baseline, Month 6Population: All enrolled participants. Here 'n' signifies number of participants evaluable for specified categories.
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their need for improvement in the frequency of each treatment received currently on a 1-5 scale, where 1 represents 'Convenient, there is no need for improvement' and 5 represents 'improvement is very necessary'. Percentage of participants with each score and ESA type was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=196 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Mircera: Score 1: Baseline (n=101)
|
98.0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Mircera: Score 2: Baseline (n=101)
|
2.0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Mircera: Score 3: Baseline (n=101)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Mircera: Score 4: Baseline (n=101)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Mircera: Score 5: Baseline (n=101)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Recormon: Score 1: Baseline (n=34)
|
94.1 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Recormon: Score 2: Baseline (n=34)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Recormon: Score 3: Baseline (n=34)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Recormon: Score 4: Baseline (n=34)
|
2.9 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Recormon: Score 5: Baseline (n=34)
|
2.9 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Eprex: Score 1: Baseline (n=21)
|
90.5 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Eprex: Score 2: Baseline (n=21)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Eprex: Score 3: Baseline (n=21)
|
9.5 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Eprex: Score 4: Baseline (n=21)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Eprex: Score 5: Baseline (n=21)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Aranesp: Score 1: Baseline (n=40)
|
90.0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Aranesp: Score 2: Baseline (n=40)
|
2.5 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Aranesp: Score 3: Baseline (n=40)
|
2.5 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Aranesp: Score 4: Baseline (n=40)
|
5.0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Aranesp: Score 5: Baseline (n=40)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Mircera: Score 1: Month 6 (n=66)
|
100.0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Mircera: Score 2: Month 6 (n=66)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Mircera: Score 3: Month 6 (n=66)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Mircera: Score 4: Month 6 (n=66)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Mircera: Score 5: Month 6 (n=66)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Recormon: Score 1: Month 6 (n=29)
|
96.6 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Recormon: Score 2: Month 6 (n=29)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Recormon: Score 3: Month 6 (n=29)
|
3.4 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Recormon: Score 4: Month 6 (n=29)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Recormon: Score 5: Month 6 (n=29)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Eprex: Score 1: Month 6 (n=19)
|
94.7 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Eprex: Score 2: Month 6 (n=19)
|
5.3 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Eprex: Score 3: Month 6 (n=19)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Eprex: Score 4: Month 6 (n=19)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Eprex: Score 5: Month 6 (n=19)
|
0 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Aranesp: Score 1: Month 6 (n=37)
|
89.2 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Aranesp: Score 2: Month 6 (n=37)
|
2.7 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Aranesp: Score 3: Month 6 (n=37)
|
2.7 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Aranesp: Score 4: Month 6 (n=37)
|
2.7 percentage of participants
|
|
Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type
Aranesp: Score 5: Month 6 (n=37)
|
2.7 percentage of participants
|
SECONDARY outcome
Timeframe: Baseline, Month 6Population: All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points.
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked "Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?". Participants answered as either once a month, twice a month, once a week, twice a week, three times a week or other (any other frequency). Percentage of participants with each preferred treatment frequency was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=196 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by Preferred Treatment Frequency
Twice a month: Baseline (n=196)
|
17.3 percentage of participants
Interval 12.3 to 23.4
|
|
Percentage of Participants by Preferred Treatment Frequency
Other: Baseline (n=196)
|
3.1 percentage of participants
Interval 1.1 to 6.5
|
|
Percentage of Participants by Preferred Treatment Frequency
Once a month: Baseline (n=196)
|
63.8 percentage of participants
Interval 56.6 to 70.5
|
|
Percentage of Participants by Preferred Treatment Frequency
Once a month: Month 6 (n=151)
|
49.0 percentage of participants
Interval 40.8 to 57.3
|
|
Percentage of Participants by Preferred Treatment Frequency
Twice a month: Month 6 (n=151)
|
23.8 percentage of participants
Interval 17.3 to 31.4
|
|
Percentage of Participants by Preferred Treatment Frequency
Once a week: Baseline (n=196)
|
12.8 percentage of participants
Interval 8.4 to 18.3
|
|
Percentage of Participants by Preferred Treatment Frequency
Once a week: Month 6 (n=151)
|
17.2 percentage of participants
Interval 11.6 to 24.2
|
|
Percentage of Participants by Preferred Treatment Frequency
Twice a week: Baseline (n=196)
|
2.0 percentage of participants
Interval 0.6 to 5.1
|
|
Percentage of Participants by Preferred Treatment Frequency
Twice a week: Month 6 (n=151)
|
2.0 percentage of participants
Interval 0.4 to 5.7
|
|
Percentage of Participants by Preferred Treatment Frequency
Three times a week: Baseline (n=196)
|
1.0 percentage of participants
Interval 0.1 to 3.6
|
|
Percentage of Participants by Preferred Treatment Frequency
Other: Month 6 (n=151)
|
7.3 percentage of participants
Interval 3.7 to 12.7
|
|
Percentage of Participants by Preferred Treatment Frequency
Three times a week: Month 6 (n=151)
|
0.7 percentage of participants
Interval 0.0 to 3.6
|
SECONDARY outcome
Timeframe: Baseline, Month 6Population: All enrolled participants. Here 'n' signifies number of participants evaluable for specified categories.
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and their preference of treatment frequency. Participants were asked "Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?". Participants answered as either once a month, twice a month, once a week, twice a week, three times a week or other (any other frequency). Percentage of participants with each preferred treatment frequency and ESA type was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=196 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Recormon: Once a month: Month 6 (n=29)
|
27.6 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Recormon: Twice a month: Baseline (n=34)
|
14.7 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Recormon: Twice a month: Month 6 (n=29)
|
31.0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Recormon: Once a week: Baseline (n=34)
|
35.3 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Recormon: Once a week: Month 6 (n=29)
|
31.0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Recormon: Twice a week: Baseline (n=34)
|
2.9 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Recormon: Twice a week: Month 6 (n=29)
|
6.9 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Recormon: Three times a week: Baseline (n=34)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Recormon: Three times a week: Month 6 (n=29)
|
3.4 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Recormon: Other: Baseline (n=34)
|
2.9 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Recormon: Other: Month 6 (n=29)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Eprex: Once a month: Baseline (n=21)
|
33.3 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Eprex: Once a month: Month 6 (n=19)
|
10.5 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Eprex: Twice a month: Baseline (n=21)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Eprex: Twice a month: Month 6 (n=19)
|
15.8 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Eprex: Once a week: Baseline (n=21)
|
42.9 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Eprex: Once a week: Month 6 (n=19)
|
52.6 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Eprex: Twice a week: Baseline (n=21)
|
9.5 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Eprex: Twice a week: Month 6 (n=19)
|
5.3 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Mircera: Once a month: Baseline (n=101)
|
83.2 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Mircera: Once a month: Month 6 (n=66)
|
75.8 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Mircera: Twice a month: Baseline (n=101)
|
14.9 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Mircera: Twice a month: Month 6 (n=66)
|
15.2 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Mircera: Once a week: Baseline (n=101)
|
1.0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Mircera: Once a week: Month 6 (n=66)
|
3.0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Mircera: Twice a week: Baseline (n=101)
|
1.0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Mircera: Twice a week: Month 6 (n=66)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Mircera: Three times a week: Baseline (n=101)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Mircera: Three times a week: Month 6 (n=66)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Mircera: Other: Baseline (n=101)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Mircera: Other: Month 6 (n=66)
|
6.1 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Recormon: Once a month: Baseline (n=34)
|
44.1 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Eprex: Three times a week: Baseline (n=21)
|
4.8 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Eprex: Three times a week: Month 6 (n=19)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Eprex: Other: Baseline (n=21)
|
9.5 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Eprex: Other: Month 6 (n=19)
|
15.8 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Aranesp: Once a month: Baseline (n=40)
|
47.5 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Aranesp: Once a month: Month 6 (n=37)
|
37.8 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Aranesp: Twice a month: Baseline (n=40)
|
35.0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Aranesp: Twice a month: Month 6 (n=37)
|
37.8 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Aranesp: Once a week: Baseline (n=40)
|
7.5 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Aranesp: Once a week: Month 6 (n=37)
|
13.5 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Aranesp: Twice a week: Baseline (n=40)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Aranesp: Twice a week: Month 6 (n=37)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Aranesp: Three times a week: Baseline (n=40)
|
2.5 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Aranesp: Three times a week: Month 6 (n=37)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Aranesp: Other: Baseline (n=40)
|
7.5 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by ESA Type
Aranesp: Other: Month 6 (n=37)
|
10.8 percentage of participants
|
SECONDARY outcome
Timeframe: Baseline, Month 6Population: All enrolled participants. Number of participants analyzed = participants evaluable for this outcome measure. Here 'n' signifies number of participants evaluable for specified categories.
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for their preference of treatment frequency and baseline ESA frequency. Participants were asked "Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?". Preferred treatment frequency included: once a month (O/M), twice a month (B/M), once a week (O/W), twice a week (B/W), three times a week (T/W) or other (any other frequency\]). Frequency of baseline ESA use included: three times a week, twice a week, once a week, every 2 weeks (Q2W), every 4 weeks (Q4W) or other (any other frequency). Percentage of participants by each preferred treatment frequency and baseline ESA frequency was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=195 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/M: Baseline ESA Q2W: Baseline (n=51)
|
49.0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/M: Baseline ESA Q4W: Month 6 (n=59)
|
96.6 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/W: Baseline ESA Q4W: Baseline (n=75)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/M: Baseline ESA Q2W: Baseline (n=51)
|
47.1 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/M: Baseline ESA Q2W: Month 6 (n=38)
|
81.6 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/M: Baseline ESA Q4W: Baseline (n=75)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/M: Baseline ESA Q4W: Month 6 (n=59)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/M: Baseline ESA other: Baseline (n=21)
|
9.5 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/M: Baseline ESA other: Month 6 (n=22)
|
4.5 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/W: Baseline ESA T/W: Baseline (n=5)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/W: Baseline ESA T/W: Month 6 (n=2)
|
50.0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred T/W: Baseline ESA Q4W: Baseline (n=75)
|
1.3 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred T/W: Baseline ESA Q4W: Month 6 (n=59)
|
1.7 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred T/W: Baseline ESA other: Baseline (n=21)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred T/W: Baseline ESA other: Month 6 (n=22)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred Other: Baseline ESA T/W: Baseline (n=5)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred Other: Baseline ESA T/W: Month 6 (n=2)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred Other: Baseline ESA B/W: Baseline (n=14)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/W: Baseline ESA B/W: Baseline (n=14)
|
28.6 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/W: Baseline ESA B/W: Month 6 (n=6)
|
33.3 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/W: Baseline ESA O/W: Baseline (n=29)
|
62.1 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/W: Baseline ESA O/W: Month 6 (n=24)
|
79.2 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/W: Baseline ESA Q2W: Baseline (n=51)
|
2.0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/W: Baseline ESA Q2W: Month 6 (n=38)
|
2.6 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/W: Baseline ESA Q4W: Month 6 (n=59)
|
1.7 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/W: Baseline ESA other: Baseline (n=21)
|
9.5 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/W: Baseline ESA other: Month 6 (n=22)
|
9.1 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/W: Baseline ESA T/W: Baseline (n=5)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/W: Baseline ESA T/W: Month 6 (n=2)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/W: Baseline ESA B/W: Baseline (n=14)
|
14.3 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/W: Baseline ESA B/W: Month 6 (n=6)
|
33.3 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/W: Baseline ESA O/W: Baseline (n=29)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/W: Baseline ESA O/W: Month 6 (n=24)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/W: Baseline ESA Q2W: Baseline (n=51)
|
2.0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/W: Baseline ESA Q2W: Month 6 (n=38)
|
2.6 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/W: Baseline ESA Q4W: Baseline (n=75)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/W: Baseline ESA Q4W: Month 6 (n=59)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/W: ESA other: Baseline (n=21)
|
4.8 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred T/W: Baseline ESA T/W: Month 6 (n=2)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred T/W: Baseline ESA B/W: Baseline (n=14)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/W: ESA other: Month 6 (n=22)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred T/W: Baseline ESA T/W: Baseline (n=5)
|
20.0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred T/W: Baseline ESA B/W: Month 6 (n=6)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred T/W: Baseline ESA O/W: Baseline (n=29)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred T/W: Baseline ESA O/W: Month 6 (n=24)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred T/W: Baseline ESA Q2W: Baseline (n=51)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred T/W: Baseline ESA Q2W: Month 6 (n=38)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred Other: Baseline ESA B/W: Month 6 (n=6)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred Other: Baseline ESA O/W: Month 6 (n=29)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred Other: Baseline ESA O/W: Month 6 (n=24)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred Other: Baseline ESA Q2W: Baseline (n=51)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred Other: Baseline ESA Q2W: Month 6 (n=38)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred Other: Baseline ESA Q4W: Baseline (n=75)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred Other: Baseline ESA Q4W: Month 6 (n=59)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred Other:Baseline ESA other:Baseline (n=21)
|
28.6 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred Other:Baseline ESA other: Month 6 (n=22)
|
50.0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/M: Baseline ESA B/W: Baseline (n=14)
|
28.6 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/M: Baseline ESA B/W: Month 6 (n=6)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/M: Baseline ESA O/W: Baseline (n=29)
|
27.6 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/M: Baseline ESA O/W: Month 6 (n=24)
|
12.5 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/M: Baseline ESA Q2W: Month 6 (n=38)
|
13.2 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/M: Baseline ESA Q4W: Baseline (n=75)
|
98.7 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/M: Baseline ESA other: Baseline (n=21)
|
47.6 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/M: Baseline ESA other: Month 6 (n=22)
|
36.4 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/M: Baseline ESA T/W: Baseline (n=5)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/M: Baseline ESA T/W: Month 6 (n=2)
|
0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/M: Baseline ESA B/W: Baseline (n=14)
|
28.6 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/M: Baseline ESA B/W: Month 6 (n=6)
|
33.3 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/M: Baseline ESA O/W: Baseline (n=29)
|
10.3 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred B/M: Baseline ESA O/W: Month 6 (n=24)
|
8.3 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/M: Baseline ESA T/W: Baseline (n=5)
|
80.0 percentage of participants
|
|
Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency
Preferred O/M: Baseline ESA T/W: Month 6 (n=2)
|
50.0 percentage of participants
|
SECONDARY outcome
Timeframe: Baseline, Month 6Population: All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points.
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their limitation of daily life due to ESA refrigeration requirements on a 1-5 scale, where 1 represents 'Does not limit' and 5 represents 'significantly limits'. Percentage of participants with each score was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=196 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements
Score 3: Month 6 (n=151)
|
1.3 percentage of participants
Interval 0.2 to 4.7
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements
Score 1: Baseline (n=196)
|
96.4 percentage of participants
Interval 92.8 to 98.6
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements
Score 1: Month 6 (n=151)
|
97.4 percentage of participants
Interval 93.4 to 99.3
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements
Score 2: Baseline (n=196)
|
1.0 percentage of participants
Interval 0.1 to 3.6
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements
Score 2: Month 6 (n=151)
|
0.7 percentage of participants
Interval 0.0 to 3.6
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements
Score 3: Baseline (n=196)
|
0 percentage of participants
Interval 0.0 to 0.0
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements
Score 4: Baseline (n=196)
|
0.5 percentage of participants
Interval 0.0 to 2.8
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements
Score 4: Month 6 (n=151)
|
0 percentage of participants
Interval 0.0 to 0.0
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements
Score 5: Baseline (n=196)
|
2.0 percentage of participants
Interval 0.6 to 5.1
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements
Score 5: Month 6 (n=151)
|
0.7 percentage of participants
Interval 0.0 to 3.6
|
SECONDARY outcome
Timeframe: Baseline, Month 6Population: All enrolled participants. Here 'n' signifies number of participants evaluable for specified categories.
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their limitation of daily life due to ESA refrigeration requirements on a 1-5 scale, where 1 represents 'Does not limit' and 5 represents 'significantly limits'. Percentage of participants with each score and ESA type was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=196 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Recormon: Score 1: Baseline (n=34)
|
100.0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Recormon: Score 2: Baseline (n=34
|
0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Recormon: Score 4: Baseline (n=34
|
0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Recormon: Score 5: Baseline (n=34
|
0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Recormon: Score 1: Month 6 (n=29)
|
96.6 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Recormon: Score 2: Month 6 (n=29)
|
3.4 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Recormon: Score 3: Month 6 (n=29)
|
0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Recormon: Score 5: Month 6 (n=29)
|
0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Eprex: Score 1: Baseline (n=21)
|
100.0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Eprex: Score 2: Baseline (n=21)
|
0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Eprex: Score 4: Baseline (n=21)
|
0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Eprex: Score 2: Month 6 (n=19)
|
0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Eprex: Score 5: Month 6 (n=19)
|
5.3 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Aranesp: Score 2: Baseline (n=40)
|
2.5 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Aranesp: Score 4: Baseline (n=40)
|
2.5 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Aranesp: Score 5: Baseline (n=40)
|
5.0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Aranesp: Score 1: Month 6 (n=37)
|
94.6 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Aranesp: Score 2: Month 6 (n=37)
|
0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Aranesp: Score 3: Month 6 (n=37)
|
5.4 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Aranesp: Score 5: Month 6 (n=37)
|
0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Eprex: Score 5: Baseline (n=21)
|
0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Eprex: Score 1: Month 6 (n=19)
|
94.7 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Eprex: Score 3: Month 6 (n=19)
|
0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Aranesp: Score 1: Baseline (n=40)
|
90.0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Mircera: Score 1: Baseline (n=101)
|
97.0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Mircera: Score 2: Baseline (n=101)
|
1.0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Mircera: Score 4: Baseline (n=101)
|
0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Mircera: Score 5: Baseline (n=101)
|
2.0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Mircera: Score 1: Month 6 (n=66)
|
100.0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Mircera: Score 2: Month 6 (n=66)
|
0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Mircera: Score 3: Month 6 (n=66)
|
0 percentage of participants
|
|
Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types
Mircera: Score 5: Month 6 (n=66)
|
0 percentage of participants
|
SECONDARY outcome
Timeframe: Baseline, Month 6Population: All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points.
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their convenience of syringe usage on a 1-5 scale, where 1 represents 'Inconvenient' and 5 represents 'Very convenient'. Percentage of participants with each score was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=196 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by Convenience of Syringe Usage
Score 1: Baseline (n=196)
|
2.0 percentage of participants
Interval 0.6 to 5.1
|
|
Percentage of Participants by Convenience of Syringe Usage
Score 3: Baseline (n=196)
|
2.6 percentage of participants
Interval 0.8 to 5.9
|
|
Percentage of Participants by Convenience of Syringe Usage
Score 4: Baseline (n=196)
|
6.6 percentage of participants
Interval 3.6 to 11.1
|
|
Percentage of Participants by Convenience of Syringe Usage
Score 5: Baseline (n=196)
|
88.8 percentage of participants
Interval 83.5 to 92.8
|
|
Percentage of Participants by Convenience of Syringe Usage
Score 1: Month 6 (n=151)
|
0.7 percentage of participants
Interval 0.0 to 3.6
|
|
Percentage of Participants by Convenience of Syringe Usage
Score 3: Month 6 (n=151)
|
2.0 percentage of participants
Interval 0.4 to 5.7
|
|
Percentage of Participants by Convenience of Syringe Usage
Score 4: Month 6 (n=151)
|
4.0 percentage of participants
Interval 1.5 to 8.4
|
|
Percentage of Participants by Convenience of Syringe Usage
Score 5: Month 6 (n=151)
|
93.4 percentage of participants
Interval 88.2 to 96.8
|
SECONDARY outcome
Timeframe: Baseline, Month 6Population: All enrolled participants. Here 'n' signifies number of participants evaluable for specified categories.
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their convenience of syringe usage on a 1-5 scale, where 1 represents 'Inconvenient' and 5 represents 'Very convenient'. Percentage of participants with each score and ESA type was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=196 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Mircera: Score 4: Month 6 (n=66)
|
1.5 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Mircera: Score 5: Month 6 (n=66)
|
98.5 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Recormon: Score 1: Baseline (n=34)
|
0 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Recormon: Score 3: Baseline (n=34)
|
2.9 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Recormon: Score 4: Baseline (n=34)
|
11.8 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Mircera: Score 1: Baseline (n=101)
|
4.0 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Mircera: Score 3: Baseline (n=101)
|
1.0 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Mircera: Score 4: Baseline (n=101)
|
5.0 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Mircera: Score 5: Baseline (n=101)
|
90.1 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Mircera: Score 1: Month 6 (n=66)
|
0 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Mircera: Score 3: Month 6 (n=66)
|
0 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Recormon: Score 5: Baseline (n=34)
|
85.3 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Recormon: Score 1: Month 6 (n=29)
|
0 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Recormon: Score 3: Month 6 (n=29)
|
3.4 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Recormon: Score 4: Month 6 (n=29)
|
6.9 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Recormon: Score 5: Month 6 (n=29)
|
89.7 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Eprex: Score 1: Baseline (n=21)
|
0 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Eprex: Score 3: Baseline (n=21)
|
0 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Eprex: Score 4: Baseline (n=21)
|
0 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Eprex: Score 5: Baseline (n=21)
|
100.0 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Eprex: Score 1: Month 6 (n=19)
|
5.3 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Eprex: Score 3: Month 6 (n=19)
|
5.3 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Eprex: Score 4: Month 6 (n=19)
|
0 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Eprex: Score 5: Month 6 (n=19)
|
89.5 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Aranesp: Score 1: Baseline (n=40)
|
0 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Aranesp: Score 3: Baseline (n=40)
|
7.5 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Aranesp: Score 4: Baseline (n=40)
|
10.0 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Aranesp: Score 5: Baseline (n=40)
|
82.5 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Aranesp: Score 1: Month 6 (n=37)
|
0 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Aranesp: Score 3: Month 6 (n=37)
|
2.7 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Aranesp: Score 4: Month 6 (n=37)
|
8.1 percentage of participants
|
|
Percentage of Participants by Convenience of Syringe Usage by ESA Type
Aranesp: Score 5: Month 6 (n=37)
|
89.2 percentage of participants
|
SECONDARY outcome
Timeframe: Baseline, Month 6Population: All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points.
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their injection site pain on a 1-5 scale, where 1 represents 'Not painful' and 5 represents 'Very painful'. Percentage of participants with each score was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=196 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by Injection Site Pain
Score 2: Month 6 (n=151)
|
6.0 percentage of participants
Interval 2.8 to 11.0
|
|
Percentage of Participants by Injection Site Pain
Score 3: Baseline (n=196)
|
1.5 percentage of participants
Interval 0.3 to 4.4
|
|
Percentage of Participants by Injection Site Pain
Score 3: Month 6 (n=151)
|
1.3 percentage of participants
Interval 0.2 to 4.7
|
|
Percentage of Participants by Injection Site Pain
Score 4: Baseline (n=196)
|
0.5 percentage of participants
Interval 0.0 to 2.8
|
|
Percentage of Participants by Injection Site Pain
Score 4: Month 6 (n=151)
|
0.7 percentage of participants
Interval 0.0 to 3.6
|
|
Percentage of Participants by Injection Site Pain
Score 5: Baseline (n=196)
|
1.0 percentage of participants
Interval 0.1 to 3.6
|
|
Percentage of Participants by Injection Site Pain
Score 5: Month 6 (n=151)
|
0 percentage of participants
Interval 0.0 to 0.0
|
|
Percentage of Participants by Injection Site Pain
Score 1: Baseline (n=196)
|
88.8 percentage of participants
Interval 83.5 to 92.8
|
|
Percentage of Participants by Injection Site Pain
Score 1: Month 6 (n=151)
|
92.1 percentage of participants
Interval 86.5 to 95.8
|
|
Percentage of Participants by Injection Site Pain
Score 2: Baseline (n=196)
|
8.2 percentage of participants
Interval 4.7 to 12.9
|
SECONDARY outcome
Timeframe: Baseline, Month 6Population: All enrolled participants. Here 'n' signifies number of participants evaluable for specified categories.
Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their injection site pain on a 1-5 scale, where 1 represents 'Not painful' and 5 represents 'Very painful'. Percentage of participants with each score and ESA type was reported.
Outcome measures
| Measure |
Chronic Renal Anemia Participants
n=196 Participants
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Percentage of Participants by Injection Site Pain by ESA Type
Eprex: Score 1: Month 6 (n=19)
|
84.2 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Eprex: Score 2: Month 6 (n=19)
|
15.8 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Eprex: Score 3: Month 6 (n=19)
|
0 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Eprex: Score 4: Month 6 (n=19)
|
0 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Aranesp: Score 2: Month 6 (n=37)
|
8.1 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Aranesp: Score 3: Month 6 (n=37)
|
5.4 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Aranesp: Score 4: Month 6 (n=37)
|
2.7 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Mircera: Score 1: Baseline (n=101)
|
92.1 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Mircera: Score 2: Baseline (n=101)
|
6.9 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Mircera: Score 3: Baseline (n=101)
|
1.0 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Mircera: Score 4: Baseline (n=101)
|
0 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Mircera: Score 5: Baseline (n=101)
|
0 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Mircera: Score 1: Month 6 (n=66)
|
97.0 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Mircera: Score 2: Month 6 (n=66)
|
3.0 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Mircera: Score 3: Month 6 (n=66)
|
0 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Mircera: Score 4: Month 6 (n=66)
|
0 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Recormon: Score 1: Baseline (n=34)
|
91.2 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Recormon: Score 2: Baseline (n=34
|
5.9 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Recormon: Score 3: Baseline (n=34)
|
2.9 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Recormon: Score 4: Baseline (n=34)
|
0 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Recormon: Score 5: Baseline (n=34)
|
0 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Recormon: Score 1: Month 6 (n=29)
|
96.6 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Recormon: Score 2: Month 6 (n=29)
|
3.4 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Recormon: Score 3: Month 6 (n=29)
|
0 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Recormon: Score 4: Month 6 (n=29)
|
0 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Eprex: Score 1: Baseline (n=21)
|
71.4 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Eprex: Score 2: Baseline (n=21)
|
23.8 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Eprex: Score 3: Baseline (n=21)
|
4.8 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Eprex: Score 4: Baseline (n=21)
|
0 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Eprex: Score 5: Baseline (n=21)
|
0 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Aranesp: Score 1: Baseline (n=40)
|
87.5 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Aranesp: Score 2: Baseline (n=40)
|
5.0 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Aranesp: Score 3: Baseline (n=40)
|
0 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Aranesp: Score 4: Baseline (n=40)
|
2.5 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Aranesp: Score 5: Baseline (n=40)
|
5.0 percentage of participants
|
|
Percentage of Participants by Injection Site Pain by ESA Type
Aranesp: Score 1: Month 6 (n=37)
|
83.8 percentage of participants
|
Adverse Events
Chronic Renal Anemia Participants
Serious events: 3 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Chronic Renal Anemia Participants
n=196 participants at risk
Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
|
|---|---|
|
Gastrointestinal disorders
Upper gastrointestinal haemorrhage
|
0.51%
1/196 • From Baseline up to Month 6
Non-serious adverse events (AEs) were not collected in this study.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.51%
1/196 • From Baseline up to Month 6
Non-serious adverse events (AEs) were not collected in this study.
|
|
Renal and urinary disorders
Chronic kidney disease
|
0.51%
1/196 • From Baseline up to Month 6
Non-serious adverse events (AEs) were not collected in this study.
|
|
General disorders
Death
|
0.51%
1/196 • From Baseline up to Month 6
Non-serious adverse events (AEs) were not collected in this study.
|
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
- Publication restrictions are in place
Restriction type: OTHER